NASDAQ
25.29USD
-1.14 (-4.31%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
3.2B
P/E
—
EPS
—
Beta
1.53
52W range
14.03-31.77
Day range
25.27–26.88
Open
26.68
Prev close
26.43
Volume
2.4M
Avg volume
1.8M
Dividend
0.00
IPO
2020-01-31
https://www.zacks.com/stock/news/2957225/wall-street-analysts-think-arcutis-biotherapeutics-arqt-could-surge-25-79-read-this-before-placing-a-bet?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|consensus_price_target-2957225 · 7/21/2026+0.80
https://www.investors.com/research/biotech-stock-arcutis-biotherapeutics-arqt-skin-dermatology-health-markets-investing/ · 7/9/2026+0.90
https://www.globenewswire.com/news-release/2026/06/30/3319793/0/en/Arcutis-Launches-New-Virtual-Health-Platform-Supporting-Access-to-Care-for-Individuals-Living-with-Chronic-Inflammatory-Skin-Diseases-Including-Approved-ZORYVE-roflumilast-Indicati.html · 6/30/2026+0.80
https://www.defenseworld.net/2026/04/19/comparing-quantum-biopharma-nasdaqqntm-arcutis-biotherapeutics-nasdaqarqt.html · 4/19/2026+0.80
https://www.fool.com/coverage/filings/2026/04/08/arcutis-stock-up-65-as-director-sells-10-000-shares-under-10b5-1-plan-here-s-what-investors-should-know/ · 4/8/2026+0.80
https://www.zacks.com/stock/news/2793543/arcutis-biotherapeutics-inc-arqt-soars-to-52-week-high-time-to-cash-out?cid=CS-STOCKNEWSAPI-FT-52_week_high-2793543 · 11/20/2025+1.00
https://www.zacks.com/stock/news/2791891/are-medical-stocks-lagging-brightspring-health-services-inc-btsg-this-year?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_1-2791891 · 11/17/2025+0.80
https://seekingalpha.com/article/4834412-arcutis-q3-increased-foam-share-better-gtn-clear-2026-guide-drive-stock-up · 10/29/2025+1.00
https://www.zacks.com/stock/news/2760123/arcutis-biotherapeutics-inc-arqt-hit-a-52-week-high-can-the-run-continue?cid=CS-STOCKNEWSAPI-FT-52_week_high-2760123 · 10/1/2025+0.80
https://www.globenewswire.com/news-release/2025/09/16/3150850/0/en/Allure-Magazine-Honors-Arcutis-ZORYVE-roflumilast-with-Prestigious-Best-of-Beauty-Breakthrough-Award.html · 9/16/2025+0.80
https://www.globenewswire.com/news-release/2025/09/03/3143473/0/en/Palvella-Therapeutics-Strengthens-Leadership-with-Appointment-of-Accomplished-Scientist-and-Biopharmaceutical-Executive-David-W-Osborne-Ph-D-as-Chief-Innovation-Officer.html · 9/3/2025+0.00
https://www.zacks.com/stock/news/2745531/does-arcutis-biotherapeutics-arqt-have-the-potential-to-rally-45-81-as-wall-street-analysts-expect?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|consensus_price_target-2745531 · 9/1/2025+0.80
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
